-
摘要: 细胞游离DNA(cfDNA)是存在于体液中、游离于细胞外的DNA片段,其主要来源于血细胞、组织细胞、脂肪细胞等,在特定条件下还可能来源于肿瘤、移植物或胎儿等。随着精准医疗时代的到来,基于cfDNA检测的液体活组织检查技术在产前诊断、恶性肿瘤以及器官移植等领域中具有明显优势,其无创诊断、治疗监测以及预后评估等方面受到广泛关注。本文就cfDNA的生物学基础、cfDNA在器官移植中的应用做一综述。
-
[1] SNYDER MW, KIRCHER M, HILL AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin[J]. Cell, 2016, 164(1/2): 57-68. DOI: 10.1016/j.cell.2015.11.050. [2] CELEC P, VLKOVÁ B, LAUKOVÁ L, et al. Cell-free DNA: the role in pathophysiology and as a biomarker in kidney diseases[J]. Expert Rev Mol Med, 2018, 20: e1. DOI: 10.1017/erm.2017.12. [3] ALLAM R, KUMAR SV, DARISIPUDI MN, et al. Extracellular histones in tissue injury and inflammation[J]. J Mol Med (Berl), 2014, 92(5): 465-472. DOI: 10.1007/s00109-014-1148-z. [4] ULZ P, HEITZER E, GEIGL JB, et al. Patient monitoring through liquid biopsies using circulating tumor DNA[J]. Int J Cancer, 2017, 141(5): 887-896. DOI: 10.1002/ijc.30759. [5] YU SC, LEE SW, JIANG P, et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing[J]. Clin Chem, 2013, 59(8): 1228-1237. DOI: 10.1373/clinchem.2013.203679. [6] KHIER S, LOHAN L. Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature[J]. Future Sci OA, 2018, 4(4): FSO295. DOI: 10.4155/fsoa-2017-0140. [7] TOSEVSKA A, FRANZKE B, HOFMANN M, et al. Circulating cell-free DNA, telomere length and bilirubin in the vienna active ageing study: exploratory analysis of a randomized, controlled trial[J]. Sci Rep, 2016, 6: 38084. DOI: 10.1038/srep38084. [8] LUCEY MR, TERRAULT N, OJO L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(1): 3-26. DOI: 10.1002/lt.23566. [9] MEEUSEN JW, LIESKE JC. Looking for a better creatinine[J]. Clin Chem, 2014, 60(8):1036-1039. DOI: 10.1373/clinchem.2013.220764. [10] LO YM, TEIN MS, PANG CC, et al. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients[J]. Lancet, 1998, 351(9112): 1329-1330. doi: 10.1016/S0140-6736(05)79055-3 [11] BECK J, OELLERICH M, SCHULZ U, et al. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation[J]. Transplant Proc, 2015, 47(8): 2400-2403. DOI: 10.1016/j.transproceed.2015.08.035. [12] GIELIS EM, LEDEGANCK KJ, DE WINTER BY, et al. Cell-free DNA: an upcoming biomarker in transplantation[J]. Am J Transplant, 2015, 15(10): 2541-2551. DOI: 10.1111/ajt.13387. [13] DE VLAMINCK I, MARTIN L, KERTESZ M, et al. Noninvasive monitoring of infection and rejection after lung transplantation[J]. Proc Natl Acad Sci U S A, 2015, 112(43): 13336-13341. DOI: 10.1073/pnas.1517494112. [14] DE VLAMINCK I, VALANTINE HA, SNYDER TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection[J]. Sci Transl Med, 2014, 6(241): 241ra77. DOI: 10.1126/scitranslmed.3007803. [15] BECK J, BIERAU S, BALZER S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury[J]. Clin Chem, 2013, 59(12): 1732-1741. DOI: 10.1373/clinchem.2013.210328. [16] SCHÜTZ E, FISCHER A, BECK J, et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: a prospective, observational, multicenter cohort study[J]. PLoS Med, 2017, 14(4): e1002286. DOI: 10.1371/journal.pmed.1002286. [17] SUN K, JIANG P, CHAN KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments[J]. Proc Natl Acad Sci U S A, 2015, 112(40): E5503-E5512. DOI: 10.1073/pnas.1508736112. [18] BLOOM RD, BROMBERG JS, POGGIO ED, et al. Cell-free DNA and active rejection in kidney allografts[J]. J Am Soc Nephrol, 2017, 28(7): 2221-2232. DOI: 10.1681/ASN.2016091034. [19] BROMBERG JS, BRENNAN DC, POGGIO E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications[J]. J Appl Lab Med, 2017, 2(3): 309-321. DOI: 10.1373/jalm.2016.022731. [20] OELLERICH M, SCHÜTZ E, KANZOW P, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation[J]. Ther Drug Monit, 2014, 36(2): 136-140. DOI: 10.1097/FTD.0000000000000044. [21] OELLERICH M, WALSON PD, BECK J, et al. Graft-derived cell-free DNA as a marker of transplant graft injury[J]. Ther Drug Monit, 2016, 38(Suppl 1): S75-S79. DOI: 10.1097/FTD.0000000000000239.
点击查看大图
计量
- 文章访问数: 240
- HTML全文浏览量: 215
- PDF下载量: 21
- 被引次数: 0